FINWIRES · TerminalLIVE
FINWIRES

$AXSM

9 stories mentioning AXSM

Every FINWIRES story that references AXSM, newest first.

Wire

Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says

Axsome Therapeutics (AXSM) is seeing continued momentum for its antidepressant Auvelity in major depressive disorder, alongside increasing attention following its FDA approval in Alzheimer's disease agitation, Oppenheimer said in a Wednesday note.The analysts pointed to strong performance in Auvelity's MDD launch and growing investor focus on the Alzheimer's disease agitation indication and its expected uptake trajectory.Oppenheimer also raised peak sales expectations for Auvelity to about $8 billion, driven by broader label expansion, expanded salesforce reach, and growing overlap between MDD and ADA prescribing populations, according to the report.The upcoming catalysts, including the Phase 3 Sunosi readout in binge eating disorder expected in the second half of the year, along with additional pipeline assets and business development opportunities, could further support upside potential for the stock, the report added.Oppenheimer has an outperform rating on the stock with a $280 price target.Price: $233.67, Change: $-0.53, Percent Change: -0.23%

$AXSM
Sectors

Sector Update: Health Care Stocks Flat to Lower Premarket Monday

Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Indivior Pharmaceuticals (INDV) shares were up more than 2% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.Axsome Therapeutics (AXSM) stock was up more than 3% after the company reported higher Q1 revenue while its loss per share increased.ADMA Biologics (ADMA) shares were 0.8% higher after the company said it received US Food and Drug Administration approval for the supplemental biologics license application to expand the label of its Asceniv therapy.

$ADMA$AXSM$IBB$INDV$XLV
Sectors

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.

$AXSM$LLY$NVO$QURE
Wire

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM
Research

Update: Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating

(Updated to keep price target unchanged).Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $222.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AXSM
Wire

Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating

Axsome Therapeutics (AXSM) has an average rating of buy and mean price target of $222.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $185.08, Change: $+0.08, Percent Change: +0.04%

$AXSM
Wire

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating

Axsome Therapeutics (AXSM) has an average rating of Buy and mean price target of $225.25, according to analysts polled by FactSet.Price: $188.87, Change: $+1.53, Percent Change: +0.81%

$AXSM
Insider Trading

Axsome Therapeutics Insider Sold Shares Worth $1,368,150, According to a Recent SEC Filing

Ari Maizel, Chief Commercial Officer, on April 22, 2026, sold 7,500 shares in Axsome Therapeutics (AXSM) for $1,368,150.SEC Filing:https://www.sec.gov/Archives/edgar/data/1579428/000119312526174415/xslF345X05/ownership.xml

$AXSM
Wire

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

Axsome Therapeutics' (AXSM) shares are likely facing an "attractive setup" ahead of the US Food and Drug Administration's approval decision of a label expansion of Auvelity into Alzheimer's disease agitation, Oppenheimer said in a note Tuesday.Oppenheimer said it forecasts a 20% upside with a 95% probability versus a 35% downside upon the FDA's decision, reflecting the investment firm's about $2 billion sales estimate, with a priority review for the drug backing its conviction.The investment firm noted Auvelity was originally approved for major depressive disorder in Q3 2022, and was also given breakthrough therapy designation for a potential label expansion into Alzheimer's disease agitation.Oppenheimer said it sees "distinct commercial advantages" for Auvelity, as it may "compete on clean safety, which also justifies formulary positioning and longer-term use" compared with competing Alzheimer's disease agitation drug Rexulti.Meanwhile, Auvelity is also competitively well-positioned compared with candidate drugs in development like Cobenfy, which are "far behind," the note said.Oppenheimer has an outperform rating on Axsome and a $220 price target.Price: $183.26, Change: $-5.43, Percent Change: -2.88%

$AXSM
AXSM News | FINWIRES